1. [CASE 1 — QUESTION 1] A 64-year-old woman with type 2 diabetes mellitus and stage 2 chronic kidney disease presents to the emergency department with fever (38.9°C), rigors, flank pain, and dysuria for 48 hours. She has a blood pressure of 88/54 mmHg on arrival and receives 2 liters of normal saline with improvement to 104/68 mmHg. Blood cultures (2 sets) and a urine culture are drawn. Urinalysis shows 3+ leukocyte esterase, numerous bacteria, and 50-100 white blood cells per high-power field. She is started empirically on IV ceftriaxone plus IV vancomycin pending cultures. On hospital day 2, blood cultures (both sets, 4/4 bottles) and urine culture grow E. coli. The isolate susceptibility panel returns: ampicillin resistant, ciprofloxacin resistant, ceftriaxone resistant (MIC 8 mg/L), piperacillin-tazobactam susceptible (MIC 8/4 mg/L), ertapenem susceptible (MIC 0.015 mg/L), meropenem susceptible (MIC 0.03 mg/L). ESBL phenotypic confirmation testing is pending. The infectious disease team is called to guide definitive antibiotic therapy. Which of the following is the most appropriate definitive antibiotic for this patient's bacteremia?

• A) Ceftriaxone should be continued as definitive therapy because the organism's MIC of 8 mg/L is technically within the susceptible range for non-meningeal infections when targeted pharmacokinetic dosing is applied; given the patient's stage 2 CKD with reduced drug clearance, ceftriaxone will accumulate to concentrations that maintain fT>MIC above the resistance threshold throughout the dosing interval, providing equivalent efficacy to carbapenems while avoiding carbapenem selective pressure
• B) Piperacillin-tazobactam is the appropriate carbapenem-sparing definitive therapy; the isolate tests susceptible, tazobactam inhibits ESBL activity, and a prospective randomized controlled trial (the MERINO trial) demonstrated that piperacillin-tazobactam is equivalent to meropenem for ceftriaxone-resistant Enterobacterales bacteremia at standard dosing — supporting its use as a definitive agent when carbapenems are not needed
• C) Ertapenem or meropenem is the appropriate definitive therapy for this ESBL-producing E. coli bacteremia; the MERINO trial demonstrated that piperacillin-tazobactam was inferior to meropenem for ceftriaxone-resistant Enterobacterales bacteremia, with significantly higher 30-day mortality in the piperacillin-tazobactam arm, attributable to the inoculum effect in high-bacterial-burden bacteremia — a carbapenem is the correct definitive choice regardless of piperacillin-tazobactam in vitro susceptibility
• D) Ciprofloxacin should be used as oral step-down from day 2 onward given that the patient has stabilized with IV fluids; ciprofloxacin oral bioavailability of 70-80% and urinary concentration allow early transition to outpatient therapy, and the ciprofloxacin resistance reported on the susceptibility panel reflects testing at the urinary breakpoint only — the systemic (serum) breakpoint is 4-fold higher and the isolate is susceptible at that threshold
• E) Vancomycin should be continued as part of definitive therapy for this E. coli bacteremia because Gram-negative bacteremia is best treated empirically with a regimen active against MRSA until repeat blood cultures at 48 hours confirm absence of co-bacteremia with MRSA; replacing vancomycin with carbapenem monotherapy before repeat blood culture results return is premature de-escalation that risks undertreating an occult MRSA co-infection

2. [CASE 1 — QUESTION 2] Continuing with the same patient. She is transitioned to ertapenem 500 mg IV once daily (dose-adjusted for CKD, CrCl 38 mL/min). By hospital day 4 she is afebrile (temperature 36.8°C), hemodynamically normal, tolerating a full oral diet, and her repeat blood cultures drawn at 48 hours have been negative. The urinary source is a 1.2 cm obstructing right ureteral stone confirmed on CT; urology places a ureteral stent on day 4 achieving source control. The isolate's susceptibility panel is now complete: susceptible to ertapenem (MIC 0.015 mg/L), ciprofloxacin resistant, TMP-SMX resistant, nitrofurantoin susceptible (MIC 32 mg/L), fosfomycin susceptible (MIC 8 mg/L). The team discusses oral step-down to facilitate hospital discharge. Which of the following best characterizes the most appropriate oral step-down decision at this point?

• A) Oral step-down to fosfomycin trometamol 3 g single dose is not appropriate here despite in vitro susceptibility; fosfomycin is approved only for uncomplicated lower urinary tract infection and achieves adequate therapeutic concentrations only in the urine — serum and tissue concentrations after oral dosing are well below the MIC for bacteremia; since this patient had bacteremia (now cleared), the appropriate step-down is to an agent with documented systemic pharmacokinetic distribution, and the absence of an oral agent with susceptibility and adequate systemic exposure indicates that IV ertapenem should be continued to complete the course, with close outpatient follow-up arranged
• B) Nitrofurantoin 100 mg oral twice daily is appropriate as step-down for this patient because the isolate is susceptible, the urinary source has been controlled with the ureteral stent, bacteremia has cleared, and nitrofurantoin's urinary concentration makes it the ideal agent for preventing recurrent UTI from the urinary reservoir; the risk of systemic relapse after blood culture clearance at 48 hours is negligible, so urinary-concentrated therapy is sufficient for the remainder of the antibiotic course
• C) Oral step-down is contraindicated for any E. coli bacteremia with a structural urinary source (obstructing stone) because instrumentation of the urinary tract (stent placement) introduces a 72-hour window of elevated bacteremia risk from disrupted mucosal barrier; IV carbapenem must be continued for at least 72 hours after stent placement before any oral step-down is considered, regardless of clinical stability or blood culture negativity
• D) Trimethoprim-sulfamethoxazole should be used for oral step-down despite the resistance result, because TMP-SMX resistance in E. coli on susceptibility panels reflects elevated CLSI breakpoints set for severely immunocompromised patients; for a non-immunocompromised patient with CKD, the standard serum TMP-SMX concentration achieved with oral dosing exceeds the actual MIC in 80% of susceptible E. coli isolates that are reported resistant by current breakpoints
• E) Oral step-down to any agent is premature until a 14-day IV ertapenem course is completed; current IDSA guidelines for E. coli bacteremia with obstructing urolithiasis require a minimum 14-day IV course following source control because the uroepithelial biofilm formed during obstruction creates a persistent reservoir that oral agents cannot penetrate; the negative 48-hour blood culture does not indicate bacterial clearance from the uroepithelial reservoir

3. [CASE 1 — QUESTION 3] Continuing with the same patient. She completes 10 days of IV ertapenem via OPAT (outpatient parenteral antibiotic therapy) with clinical cure. The ureteral stent is removed at 6 weeks. Two months later she returns to clinic with new onset of dysuria and frequency without fever, normal vital signs, and urinalysis showing 2+ leukocyte esterase with bacteriuria. Urine culture again grows ESBL-producing E. coli susceptible to fosfomycin (MIC 8 mg/L), ertapenem, and meropenem; resistant to ampicillin, ciprofloxacin, ceftriaxone, and TMP-SMX. Physical examination confirms no costovertebral angle tenderness and no systemic features. Blood cultures are not drawn given the uncomplicated presentation. Her primary care physician asks whether a carbapenem is required given the ESBL phenotype, or whether fosfomycin trometamol single dose is appropriate. Which of the following best characterizes the correct treatment decision and the pharmacological rationale?

• A) Ertapenem 1 g IV once daily for 5 days is required because ESBL-producing organisms with resistance to ciprofloxacin and TMP-SMX are always treated with carbapenems regardless of infection site or severity; any non-carbapenem therapy for ESBL E. coli infections risks selecting for carbapenemase production through mutational evolution during sub-optimal antibiotic exposure
• B) Oral nitrofurantoin 100 mg twice daily for 5 days is preferred over fosfomycin for this uncomplicated cystitis because nitrofurantoin has a lower resistance rate among ESBL-producing E. coli globally and multiple randomized trials have demonstrated microbiological cure superiority of nitrofurantoin over fosfomycin single dose specifically for ESBL-producing organisms
• C) Fosfomycin trometamol 3 g single oral dose is not appropriate because this patient previously had ESBL bacteremia from the same organism; patients with prior ESBL bacteremia have a permanently elevated inoculum effect in all subsequent infections from the same organism, meaning urinary fosfomycin concentrations that are adequate for naive ESBL cystitis are insufficient for recurrent ESBL cystitis in patients with prior bacteremia
• D) Oral step-down to TMP-SMX is appropriate despite the reported resistance because urinary TMP-SMX concentrations are 100-fold higher than serum concentrations, and the urinary drug level reliably exceeds the MIC for ESBL E. coli reported as resistant by serum-based susceptibility breakpoints; IDSA guidelines specifically recommend this urinary concentration override for uncomplicated cystitis caused by TMP-SMX-resistant ESBL organisms
• E) Fosfomycin trometamol 3 g single oral dose is the appropriate therapy for this uncomplicated ESBL-producing E. coli cystitis; fosfomycin inhibits MurA and is not a beta-lactam substrate, so ESBL enzymes do not reduce its activity; oral fosfomycin achieves high urinary concentrations sufficient for uncomplicated lower UTI, is endorsed by IDSA and ESCMID guidelines for ESBL cystitis, and a carbapenem is not required for this uncomplicated presentation without systemic features or bacteremia

4. [CASE 1 — QUESTION 4] Continuing with the same patient. At a later follow-up, the patient asks her physician why the laboratory reported the E. coli susceptible to piperacillin-tazobactam initially, yet the infectious disease team overruled this result and selected a carbapenem instead. The physician recognizes this as an important teaching opportunity about the limitations of susceptibility testing for ESBL-producing organisms. Which of the following best explains the pharmacological and microbiological basis for the discordance between the piperacillin-tazobactam susceptibility result and clinical outcome data?

• A) The discordance reflects a laboratory calibration error specific to tazobactam-containing combinations; piperacillin-tazobactam disk diffusion has a documented 15% false-susceptible rate due to tazobactam degradation during shipping and storage, and clinical laboratories should use E-test methodology exclusively for piperacillin-tazobactam susceptibility testing of ESBL-producing organisms to eliminate this technical artifact
• B) Standard broth microdilution and disk diffusion susceptibility testing uses a low, standardized bacterial inoculum (approximately 5×10⁵ CFU/mL) that does not replicate in vivo bacterial densities during bacteremia; at low testing inocula, tazobactam successfully inhibits the ESBL enzyme and piperacillin reaches the PBPs effectively; at the high bacterial densities in actual bloodstream infection, ESBL enzyme production overwhelms tazobactam inhibition and reduces effective piperacillin concentrations below the MIC — this is the inoculum effect, and it systematically produces false-susceptible results for piperacillin-tazobactam against ESBL-producing Enterobacterales in bacteremia
• C) The susceptibility report uses serum-based breakpoints that are calibrated for parenteral administration; because the patient had already received oral antibiotics before hospitalization, the oral bioavailability of prior antibiotics selected for a high-efflux E. coli sub-clone within the bloodstream isolate population that is not detected at standard testing inocula but predominates in vivo during parenteral piperacillin-tazobactam therapy, producing the discordant outcome
• D) The discordance reflects species-specific testing limitations exclusive to ESBL-producing E. coli; the CLSI susceptibility breakpoints for piperacillin-tazobactam were established using only non-ESBL E. coli clinical isolates, and the breakpoints have never been validated against ESBL-producing strains; carbapenems should therefore always replace piperacillin-tazobactam in any E. coli infection regardless of susceptibility result or clinical severity
• E) The susceptibility result was accurate at the time of testing but became clinically invalid because the E. coli underwent adaptive evolution during the 24 hours between sample collection and susceptibility result reporting; bacterial populations in blood cultures that grow for extended periods before susceptibility testing acquire adaptive mutations that are not present in the freshly collected isolate and that produce false-susceptible results on the final report

5. [CASE 2 — QUESTION 1] A 58-year-old man with type 2 diabetes undergoes coronary artery bypass grafting (CABG) with median sternotomy. On post-operative day 8 he develops fever (38.7°C), sternal wound erythema, drainage, and sternal click on palpation. Blood cultures (2 sets) grow Staphylococcus aureus. Oxacillin disk diffusion shows a zone diameter of 6 mm (resistant), consistent with methicillin-resistant Staphylococcus aureus (MRSA). The intern asks why they cannot simply use high-dose nafcillin or oxacillin, which are generally considered the most potent agents against susceptible S. aureus, rather than vancomycin. Which of the following most accurately explains why no conventional beta-lactam antibiotic is active against MRSA regardless of the dose administered?

• A) MRSA produces a broad-spectrum serine beta-lactamase (PC1 beta-lactamase) that has undergone point mutations expanding its activity to hydrolyze all penicillins, all cephalosporins, and carbapenems; the hydrolytic activity is proportional to inoculum, which is why high-dose nafcillin fails even when in vitro MIC testing at low inocula suggests activity — the clinical inoculum of sternal osteomyelitis overwhelms hydrolytic capacity at standard dosing
• B) MRSA resistance to beta-lactams results from sequential point mutations in the native PBP2 transpeptidase that progressively reduce its binding affinity for all beta-lactam antibiotics; unlike the single-step acquisition of a resistance gene, this gradual affinity reduction cannot be overcome by high dosing because the affinity reduction is multiplicative across all available PBP2 molecules simultaneously, leaving no susceptible target regardless of drug concentration
• C) Beta-lactam antibiotics are physically excluded from the MRSA cell because mecA encodes an outer membrane channel protein that actively exports all beta-lactam molecules before they can reach periplasmic PBPs; this efflux mechanism is so efficient that even concentrations 1,000-fold above the MIC for susceptible S. aureus cannot achieve sufficient periplasmic accumulation to inhibit any PBP — though this efflux system specifically spares ceftaroline due to its allosteric binding to the efflux pump's substrate recognition site
• D) MRSA expresses PBP2a, an alternative transpeptidase encoded by the mecA gene, whose active site is in a conformationally closed state that all conventional beta-lactams cannot access regardless of drug concentration; when native PBPs are inhibited by beta-lactams, PBP2a continues performing transpeptidation and cell wall synthesis proceeds — no amount of dose escalation of conventional beta-lactams overcomes the structural inaccessibility of PBP2a's active site, which is why ceftaroline's allosteric mechanism (opening PBP2a's active site) is the pharmacological basis for its unique MRSA activity
• E) Beta-lactam resistance in MRSA is mediated by the blaZ gene, which encodes a constitutively hyperexpressed inducible penicillinase with 200-fold higher catalytic efficiency than wild-type PC1 beta-lactamase; this hyperactive enzyme inactivates all beta-lactam classes including anti-staphylococcal penicillins, cephalosporins, and carbapenems before they can bind any PBP, and no available beta-lactamase inhibitor has sufficient affinity for the blaZ-encoded enzyme to provide clinical protection

6. [CASE 2 — QUESTION 2] Continuing with the same patient. He is started on vancomycin for MRSA sternal wound infection and bacteremia. The MRSA isolate has a vancomycin MIC of 1 mg/L. The clinical pharmacist proposes AUC24/MIC-guided monitoring and requests two-point pharmacokinetic sampling to calculate the vancomycin AUC. The attending asks the pharmacist to explain the monitoring target and why the old trough-only approach has been superseded. Which of the following correctly describes the current evidence-based vancomycin monitoring approach for serious MRSA infections and the pharmacodynamic rationale for the AUC24/MIC target?

• A) Trough-only monitoring targeting 15-20 mg/L remains the current ASHP/IDSA/SIDP standard for serious MRSA infections; AUC-guided dosing is an investigational approach that has not been validated in prospective clinical trials for bacteremia and should only be used in academic medical centers with access to certified pharmacokinetic software — the pharmacist's proposal represents a deviation from standard of care
• B) AUC24/MIC-guided dosing with a target of 400-600 mg·h/L per mg/L is the current ASHP/IDSA/SIDP consensus standard for serious MRSA infections including bacteremia and endocarditis; vancomycin is an AUC-dependent antibiotic, and the AUC24/MIC ratio correlates with both clinical efficacy and nephrotoxicity prevention more accurately than trough monitoring alone; trough-only monitoring was superseded because it correlated poorly with actual drug exposure and led to overdosing with increased nephrotoxicity without additional clinical benefit
• C) The current vancomycin monitoring standard targets a trough-to-MIC ratio of 10:1 (trough 10 mg/L for MIC 1 mg/L); this ratio predicts bactericidal activity because vancomycin's time-dependent killing means that maintaining trough concentrations 10-fold above the MIC throughout the dosing interval ensures 100% time above MIC without requiring complex pharmacokinetic calculations; AUC monitoring is only needed when the MIC exceeds 2 mg/L
• D) Vancomycin AUC24/MIC monitoring for MRSA bacteremia targets an AUC24/MIC ratio of 1,000-1,500; this aggressive target was established because AUC/MIC ratios below 1,000 are associated with therapeutic failure in all S. aureus infections regardless of site or inoculum; achieving this target safely requires continuous vancomycin infusion rather than intermittent dosing, and the pharmacist should request pharmacy-mixed continuous infusion bags
• E) Vancomycin monitoring for MRSA endocarditis uses peak concentration (Cmax) as the primary PK/PD target; Cmax/MIC ratios above 8 are required for bactericidal activity against MRSA because vancomycin's concentration-dependent killing mode means bactericidal activity scales directly with peak serum concentration; trough monitoring underestimates the true pharmacodynamic exposure because it measures the antibiotic at its lowest concentration point

7. [CASE 2 — QUESTION 3] Continuing with the same patient. He undergoes sternal debridement and hardware removal on day 10. On day 14 of vancomycin therapy, he remains persistently bacteremic. His calculated vancomycin AUC24 is 490 mg·h/L. However, a repeat MRSA isolate from blood cultures shows the vancomycin MIC has increased to 2 mg/L (still CLSI susceptible, upper boundary). His calculated AUC24/MIC ratio is now 245 — substantially below the target of 400-600. The infectious disease team and clinical pharmacist discuss whether to increase the vancomycin dose or switch agents. Which of the following best represents the pharmacologically sound approach to this management decision?

• A) Increasing the vancomycin dose to target AUC24 of 800-1,000 mg·h/L would restore the AUC24/MIC ratio to 400-500 at the new MIC of 2 mg/L; this dose escalation is pharmacodynamically justified and safe because the nephrotoxic threshold for vancomycin has never been established in prospective trials, and maintaining vancomycin therapy avoids the transition complexity and cost of alternative agents in a patient already tolerating the drug
• B) Switching to linezolid 600 mg IV/oral twice daily is the most appropriate agent change for persistent MRSA bacteremia because linezolid is bactericidal against S. aureus and achieves superior tissue concentrations in sternal bone compared to vancomycin or daptomycin; linezolid's oral bioavailability makes it ideal for this debridement patient who will need a prolonged course of therapy with OPAT planning
• C) Switching to daptomycin at 8-10 mg/kg/day is appropriate given the persistent bacteremia and subtherapeutic AUC24/MIC ratio at the new MIC of 2 mg/L; clinical outcomes data demonstrate significantly worse results for MRSA bacteremia with vancomycin MIC 2 mg/L even when AUC targets are met, because the pharmacodynamic window narrows severely; dose escalation sufficient to restore AUC24/MIC target would require AUC24 of 800-1,200 mg·h/L with unacceptable nephrotoxicity risk
• D) Continuing current vancomycin dosing is appropriate because the AUC24/MIC ratio of 245 is below target but the MIC of 2 mg/L remains within the CLSI susceptible range; the CLSI susceptible designation overrides pharmacodynamic modeling targets, and bacteremia persistence at day 14 reflects the natural timeline of sternal MRSA osteomyelitis from incomplete surgical debridement rather than vancomycin pharmacodynamic failure
• E) Adding rifampicin 600 mg oral daily to current vancomycin is the most evidence-supported intervention for persistent MRSA bacteremia in the setting of sternal hardware infection; rifampicin's excellent bone and biofilm penetration, combined with its synergistic bactericidal activity with vancomycin, has demonstrated clinical cure superiority in all published randomized trials of persistent MRSA osteomyelitis, making it the standard of care when vancomycin AUC/MIC is subtherapeutic

8. [CASE 2 — QUESTION 4] Continuing with the same patient. He is switched to daptomycin 10 mg/kg/day. On day 8 of daptomycin therapy, his CPK (creatine phosphokinase) rises to 8,400 U/L and he develops new proximal muscle weakness — daptomycin-induced myopathy is diagnosed and daptomycin is discontinued. He remains bacteremic. The infectious disease consultant now proposes ceftaroline fosamil as salvage therapy, noting that it is the only beta-lactam with activity against MRSA. The cardiology team is skeptical that any beta-lactam can work and asks for a mechanistic explanation. Which of the following most accurately explains why ceftaroline is active against MRSA when all other beta-lactam antibiotics — at any dose — cannot inhibit PBP2a?

• A) Ceftaroline is active against MRSA because it inhibits the mecA gene transcriptional repressor, preventing production of new PBP2a molecules during therapy; as existing PBP2a is degraded by normal bacterial protein turnover, the cell wall synthesis machinery reverts to reliance on native PBPs, which are then inhibited by the cephalosporin component of ceftaroline in the standard manner; conventional beta-lactams fail because they cannot inhibit the mecA transcriptional repressor
• B) Ceftaroline achieves a pharmacokinetic advantage over other beta-lactams through its prodrug formulation (fosamil); the fosamil ester is hydrolyzed by staphylococcal esterases concentrated in the PBP2a active site rather than by plasma esterases, resulting in local drug activation at the target site and concentrations 100-fold higher than conventional beta-lactams at PBP2a; conventional beta-lactams fail because they are activated in plasma and undergo redistribution before reaching the staphylococcal cell
• C) Ceftaroline is active against MRSA because its bulky N-acyl thiazolyl side chain physically displaces PBP2a from the bacterial cell membrane by competitive membrane insertion, preventing PBP2a from performing its role in peptidoglycan synthesis without requiring active site acylation; conventional beta-lactams fail against MRSA because their smaller side chains cannot achieve the steric displacement needed to inactivate membrane-inserted PBP2a
• D) Ceftaroline's MRSA activity results from its selective inhibition of PBP1, which has uniquely retained high beta-lactam affinity in MRSA strains because the mecA-mediated resistance mechanism does not protect PBP1 from beta-lactam binding; PBP2a's transpeptidation function depends on a cooperative allosteric interaction with PBP1 that is abolished when PBP1 is inhibited by ceftaroline, making PBP2a non-functional despite remaining structurally intact; conventional beta-lactams fail because they cannot distinguish PBP1 from PBP2a and preferentially bind both with equal affinity
• E) Ceftaroline uniquely binds an allosteric sensor domain on PBP2a that is spatially distinct from the transpeptidase active site; this allosteric binding induces a conformational change that transiently opens the active site, exposing the catalytic serine for covalent inhibition in the standard beta-lactam fashion; conventional beta-lactams cannot access PBP2a's closed active site at any concentration because they lack the allosteric sensor domain engagement capacity — this structural mechanism is the sole pharmacological basis for ceftaroline's MRSA activity and cannot be replicated by dose escalation of any conventional agent

9. [CASE 3 — QUESTION 1] A 71-year-old man with end-stage renal disease on hemodialysis and a tunneled catheter is admitted to the medical ICU with ventilator-associated pneumonia. He has been hospitalized for 3 weeks following a hip fracture repair. Tracheal aspirate and bronchoalveolar lavage cultures grow Klebsiella pneumoniae. Susceptibility testing shows: meropenem resistant (MIC 16 mg/L), imipenem resistant (MIC >8 mg/L), ceftriaxone resistant, ceftazidime resistant, piperacillin-tazobactam resistant; ceftazidime-avibactam susceptible (MIC 0.5/4 mg/L). Rapid molecular testing confirms KPC-2 production. No MBL genes (NDM, VIM, IMP) are detected. The fellow asks why ceftazidime-avibactam is active against this KPC-producing isolate when all carbapenems are resistant, and why meropenem at high doses cannot be used instead. Which of the following most accurately explains the mechanism of ceftazidime-avibactam activity against KPC?

• A) Avibactam is a diazabicyclooctane non-beta-lactam inhibitor that forms a slowly reversible covalent acyl-enzyme complex with the serine residue in the KPC active site, inactivating the carbapenemase and preventing it from hydrolyzing ceftazidime; with KPC inhibited, ceftazidime is free to bind PBPs and exert its antibacterial effect; meropenem at high doses fails because the meropenem MIC of 16 mg/L reflects carbapenem hydrolysis by KPC, and no achievable serum concentration after standard or even extended-infusion meropenem dosing reliably exceeds this MIC with adequate fT>MIC
• B) Avibactam chelates the zinc ions in the KPC active site, converting KPC from a serine carbapenemase to a zinc-depleted, catalytically inactive form; ceftazidime is then protected from hydrolysis and reaches PBPs intact; meropenem fails at high doses because prolonged carbapenem exposure selects for adaptive KPC mutations that increase carbapenemase activity as a stress response, creating a dose-dependent resistance paradox
• C) Ceftazidime-avibactam is active because ceftazidime itself directly inhibits KPC through competitive binding at the carbapenemase active site with higher affinity than carbapenems; by occupying the KPC active site, ceftazidime prevents meropenem hydrolysis in combination therapy; avibactam is added to protect ceftazidime from degradation by co-produced ESBLs on the same plasmid; meropenem monotherapy fails because no competitive KPC inhibitor accompanies it
• D) KPC loses carbapenemase activity when exposed to ceftazidime-avibactam because avibactam's diazabicyclooctane ring covalently cross-links two adjacent KPC molecules, permanently inactivating the enzyme dimer; because KPC functions only as a monomer, this cross-linking is irreversible; meropenem fails because it cannot induce the cross-linking reaction, and high-dose exposure to meropenem paradoxically increases KPC dimerization
• E) Ceftazidime-avibactam reaches the KPC-producing organism's periplasm through a siderophore iron transport pathway not used by carbapenems; once inside, avibactam inhibits KPC through a zinc chelation mechanism identical to EDTA's inhibition of metallo-beta-lactamases; meropenem fails because it cannot access the siderophore pathway and is hydrolyzed before reaching the periplasm

10. [CASE 3 — QUESTION 2] Continuing with the same patient. He is started on ceftazidime-avibactam 2.5 g IV every 8 hours (dose-adjusted for ESRD with hemodialysis — standard dosing adjusted to post-dialysis scheduling). Initial clinical response is seen by day 3. On day 9 of ceftazidime-avibactam therapy, fever returns and repeat bronchoalveolar lavage cultures grow K. pneumoniae with ceftazidime-avibactam MIC now 32/4 mg/L (resistant; baseline 0.5/4 mg/L). Molecular testing identifies a D179Y substitution in the KPC-2 enzyme. No new resistance genes are detected. The infectious disease team explains to the ICU fellows what has occurred and what the D179Y mutation represents. Which of the following most accurately characterizes the D179Y mutation and its pharmacological implications?

• A) The D179Y substitution in KPC-2 converts the enzyme from a class A serine carbapenemase to a class D oxacillinase by introducing a new hydrogen bond network that eliminates serine catalytic activity and replaces it with an oxacillin-specific binding geometry; avibactam is ineffective against class D enzymes, explaining resistance, and the appropriate salvage regimen is meropenem-vaborbactam because vaborbactam is specifically active against class D oxacillinases
• B) The D179Y substitution represents plasmid acquisition of a second, avibactam-resistant KPC variant from a different K. pneumoniae strain in the ICU; whole-genome sequencing would show that the resistant isolate is a new strain with a different sequence type from the original isolate; the original KPC-2 isolate has been replaced by horizontal transfer of a D179Y-carrying plasmid into a recipient organism, not selected from the original infecting population
• C) The D179Y substitution causes constitutive KPC overexpression by inserting a strong promoter sequence upstream of the bla-KPC gene; the increased enzyme concentration overwhelms avibactam's binding capacity faster than it can be replenished by standard infusion, causing kinetic resistance; adding a continuous infusion of avibactam alone (without ceftazidime) for 24 hours would saturate the overexpressed enzyme pool and restore ceftazidime-avibactam susceptibility
• D) The D179Y substitution in KPC-2 alters the geometry of the avibactam binding pocket without eliminating carbapenemase activity; the mutant KPC retains carbapenem hydrolysis but avibactam can no longer form its stable acyl-enzyme complex at the mutated active site; this on-therapy resistance emergence is a recognized complication of ceftazidime-avibactam treatment for KPC infections and warrants consideration of aztreonam-avibactam or meropenem-vaborbactam as salvage options depending on susceptibility
• E) The D179Y mutation is selected by hemodialysis-mediated drug removal — dialysis sessions remove avibactam more rapidly than ceftazidime from the circulation due to avibactam's smaller molecular size and lower protein binding; the resulting episodic avibactam depletion during and immediately after dialysis sessions creates intermittent periods where KPC is uninhibited, selecting for organisms with reduced avibactam affinity; optimizing post-dialysis dosing timing would eliminate this selection pressure

11. [CASE 3 — QUESTION 3] Continuing with the same patient. Aztreonam-avibactam susceptibility testing is ordered emergently. The result returns: aztreonam-avibactam MIC 0.5/4 mg/L (susceptible). Meropenem-vaborbactam testing is pending. The infectious disease fellow asks why aztreonam-avibactam retains activity against the D179Y KPC variant when ceftazidime-avibactam has failed, given that the same avibactam component is used in both combinations. Which of the following most accurately explains the pharmacological rationale for aztreonam-avibactam susceptibility in the setting of D179Y KPC resistance to ceftazidime-avibactam?

• A) Avibactam's reduced affinity for the D179Y KPC variant is overcome in the aztreonam combination because aztreonam's monocyclic ring structure acts as a conformational primer that restores the avibactam binding geometry of D179Y KPC to wild-type configuration; this priming effect is concentration-dependent and explains why aztreonam-avibactam must be administered at higher avibactam ratios than ceftazidime-avibactam to maintain efficacy against avibactam-resistant variants
• B) Aztreonam-avibactam retains activity against D179Y KPC because aztreonam, as a monobactam, is not hydrolyzed by KPC regardless of whether KPC is inhibited by avibactam; KPC evolved primarily as a carbapenemase with efficient hydrolysis of bicyclic beta-lactams and extended-spectrum cephalosporins, but aztreonam's monocyclic ring structure is not an efficient KPC substrate — so aztreonam escapes KPC hydrolysis whether or not avibactam is present; avibactam's role in the combination is to inhibit co-produced serine ESBLs or other serine beta-lactamases that would otherwise hydrolyze aztreonam
• C) Aztreonam has inherently higher outer membrane penetration than ceftazidime in KPC-producing K. pneumoniae because aztreonam's sulfonate group is recognized by a TonB-dependent siderophore transporter that is not available to ceftazidime; the higher periplasmic aztreonam concentration overwhelms even uninhibited KPC, achieving bactericidal PBP3 occupancy before KPC can hydrolyze the accumulated drug
• D) The D179Y substitution specifically reduces affinity only for diazabicyclooctane (avibactam-class) inhibitors when ceftazidime is the co-administered beta-lactam; the same D179Y mutation has no effect on avibactam affinity when aztreonam is the co-administered beta-lactam because aztreonam induces a distinct KPC allosteric state that restores avibactam binding; this aztreonam-specific conformational rescue was the pharmacological basis for aztreonam-avibactam development
• E) Aztreonam-avibactam requires a new avibactam analog (avibactam-2) with a 4-fluorine substitution on the diazabicyclooctane ring that was co-formulated when aztreonam-avibactam was developed; this structural modification specifically restores avibactam inhibitory activity against D179Y KPC variants that resist the original avibactam used in ceftazidime-avibactam; the susceptibility result confirms that avibactam-2 overcomes the D179Y mutation, while original avibactam in ceftazidime-avibactam cannot

12. [CASE 3 — QUESTION 4] Continuing with the same patient. Whole-genome sequencing of the KPC-producing K. pneumoniae isolate confirms it belongs to sequence type 258 (ST258) carrying KPC-2 on an IncFII plasmid. The infection control team conducts a unit-wide investigation and finds that 3 additional patients in the ICU are colonized with the same ST258 clone by rectal surveillance swab, though none have clinical infection. The infection control practitioner presents the findings to the ICU medical staff and explains why detecting asymptomatic colonized patients is critical to outbreak control. Which of the following most accurately describes the epidemiological features of ST258 K. pneumoniae that make active surveillance necessary and contact tracing alone insufficient?

• A) ST258 is detected only in patients with severe immunosuppression (transplant, chemotherapy, HIV with CD4 <50) because its capsular polysaccharide is destroyed by normal complement in immunocompetent hosts; the 3 colonized patients found by rectal surveillance must all have occult immunosuppression, and their normal immune responses will clear colonization within 7-14 days without any antibiotic intervention required
• B) The 3 colonized patients found by rectal surveillance represent a false-positive rate of the PCR-based screening test; ST258 and non-pathogenic K. pneumoniae strains share the bla-KPC gene on an identical IncFII plasmid architecture at a frequency of 23% in unselected ICU rectal flora, meaning that approximately 1 of the 3 colonized patients actually harbors a harmless environmental K. pneumoniae with coincidental KPC; confirmatory whole-genome sequencing is required before any infection control interventions are implemented
• C) ST258 K. pneumoniae colonizes the gut at high density without producing diarrhea or any detectable clinical symptom — asymptomatic gut colonization is the primary transmission reservoir; colonized patients shed the organism in stool, contaminating hands and environmental surfaces; standard clinical surveillance detects only patients who develop infection, missing the silent colonized majority; active rectal surveillance culture is the only method to identify and cohort colonized patients before they serve as transmission sources for new ICU-onset infections
• D) ST258 produces a unique adhesin protein (fim-H ST258 isoform) that binds exclusively to the GT1b ganglioside expressed on catheterized urinary tract epithelium; transmission occurs only through shared urinary catheter circuits and is effectively controlled by dedicated catheter sets for each patient; rectal surveillance is not the most efficient screening strategy because the ST258 gut reservoir is transient and self-limiting in immunocompetent patients without urinary catheters
• E) The rectal surveillance findings indicate that the ST258 outbreak originated from a common environmental source (contaminated IV medication preparation area or ventilator circuit) rather than patient-to-patient transmission; simultaneous colonization of 3 unrelated patients without documented room proximity indicates point-source exposure rather than person-to-person spread; identifying and eliminating the environmental reservoir is more important than cohorting the colonized patients

13. [CASE 4 — QUESTION 1] A 49-year-old woman with type 2 diabetes is transferred from a hospital in India where she underwent emergency biliary surgery complicated by a prolonged ICU stay. On arrival to your facility she develops septic shock. Blood cultures grow Klebsiella pneumoniae. Initial susceptibility testing shows resistance to all carbapenems and to ceftazidime-avibactam (MIC 32/4 mg/L). Colistin susceptibility is reported (MIC 0.5 mg/L). Rapid molecular testing returns: NDM-1 positive, OXA-48 positive, KPC negative, VIM negative. The fellow asks why ceftazidime-avibactam is failing in a patient whose organism produces OXA-48 — an enzyme that avibactam should inhibit — and whether to proceed with colistin. Which of the following most accurately explains why ceftazidime-avibactam fails against this dual NDM-1 + OXA-48 co-producer?

• A) Ceftazidime-avibactam fails because the NDM-1 and OXA-48 enzymes form a hetero-dimer complex in the periplasm that structurally excludes avibactam from both active sites simultaneously; this enzyme cooperation phenomenon is specific to NDM/OXA-48 co-producers and does not occur when either enzyme is produced alone; breaking the hetero-dimer complex requires EDTA, which should be administered intravenously as adjunct therapy
• B) Ceftazidime-avibactam fails because avibactam reaches only one-quarter of its standard periplasmic concentration in NDM-producing organisms due to OprD porin downregulation, which is co-regulated with NDM expression by the same plasmid; at reduced periplasmic avibactam concentrations, OXA-48 inhibition is incomplete, allowing residual OXA-48 to hydrolyze ceftazidime even though NDM is not relevant to ceftazidime hydrolysis
• C) Ceftazidime-avibactam fails because OXA-48 in this isolate has undergone secondary mutation (OXA-48-like variant) that confers avibactam resistance; OXA-48-like variants are defined by their resistance to all currently available beta-lactamase inhibitors and are always co-produced with NDM in organisms isolated from South Asian hospitals; the combination is invariably non-susceptible in this epidemiological context regardless of the susceptibility report
• D) Ceftazidime-avibactam fails because avibactam is rapidly degraded by the elevated oxidative stress environment within NDM-producing organisms; NDM's zinc center catalyzes reactive oxygen species generation that oxidizes avibactam's diazabicyclooctane ring before it can inhibit OXA-48, leaving ceftazidime unprotected; aztreonam-avibactam overcomes this because aztreonam's sulfonate group acts as an antioxidant that protects avibactam from zinc-mediated oxidation in the periplasm
• E) Ceftazidime-avibactam fails because avibactam inhibits OXA-48 (a serine enzyme) but cannot inhibit NDM-1 (a zinc-dependent metallo-beta-lactamase with no serine active site); NDM-1 rapidly hydrolyzes ceftazidime despite OXA-48 being inhibited by avibactam — both enzymes are present and only one can be targeted; proceeding with colistin as the only currently susceptible agent is appropriate bridging while aztreonam-avibactam is urgently sourced

14. [CASE 4 — QUESTION 2] Continuing with the same patient. Aztreonam-avibactam is obtained emergently from a specialty pharmacy with infectious disease approval. Susceptibility testing confirms aztreonam-avibactam MIC of 1/4 mg/L (susceptible). The clinical pharmacist explains to the fellow why aztreonam-avibactam is expected to work against an isolate that resists both carbapenems and ceftazidime-avibactam, and why the same avibactam component that failed in ceftazidime-avibactam is expected to work here. Which of the following is the most accurate pharmacological explanation?

• A) Aztreonam-avibactam is active against this NDM-1 + OXA-48 co-producer because aztreonam's monobactam ring structure is not efficiently hydrolyzed by NDM-1 or other MBLs (which evolved to cleave bicyclic beta-lactam rings), so aztreonam bypasses the MBL resistance; avibactam in the combination inhibits OXA-48 (and any co-produced class A serine enzymes) that would otherwise hydrolyze aztreonam — the combination covers both resistance mechanisms because each component handles the enzyme class that the other cannot address
• B) Aztreonam-avibactam is active because avibactam in this formulation contains a boron-based structural modification that provides zinc ion chelation capability absent from the ceftazidime-avibactam avibactam formulation; the chelating avibactam in aztreonam-avibactam inactivates NDM-1's zinc active site directly, while the standard avibactam inhibits OXA-48; this dual-target avibactam is co-developed specifically for NDM+OXA-48 co-producers
• C) Aztreonam-avibactam is active because aztreonam competitively inhibits NDM-1 at its zinc active site by mimicking a zinc-chelating natural product that binds with higher affinity than the natural substrates; this NDM-1 inhibitory activity is specific to aztreonam and absent from all beta-lactam carbapenem antibiotics because carbapenems lack aztreonam's N-sulfonyl moiety which is the zinc-binding pharmacophore
• D) Aztreonam-avibactam is active because the combination is administered at a 10:1 aztreonam:avibactam molar ratio that overwhelms NDM-1 numerically; NDM-1 can only hydrolyze one aztreonam molecule at a time, and delivering 10 aztreonam molecules per avibactam molecule ensures that enough intact aztreonam molecules reach PBPs even after partial NDM-1 hydrolysis; ceftazidime-avibactam failed because the 1:4 ceftazidime:avibactam ratio provides insufficient ceftazidime substrate to overcome NDM-1 hydrolysis numerically
• E) Aztreonam-avibactam is active because avibactam at the concentrations achieved with the aztreonam-avibactam formulation (which uses double the avibactam dose of ceftazidime-avibactam) achieves sufficient periplasmic concentration to inhibit both NDM-1 and OXA-48 simultaneously; the higher avibactam dose in the aztreonam-avibactam preparation also provides kinetic NDM-1 inhibition through competitive displacement of zinc ions at the active site

15. [CASE 4 — QUESTION 3] Continuing with the same patient. While awaiting aztreonam-avibactam, the patient receives 72 hours of colistin. During this period the infection control team notes that a second patient in the same unit — a 55-year-old man recently returned from agricultural work in China — also has an NDM-producing E. coli isolate that is colistin-resistant. PCR testing of his isolate confirms the mcr-1 gene. The infectious disease consultant uses this concurrent case to explain the difference between chromosomal polymyxin resistance (as might emerge during colistin therapy) and mcr-1-mediated resistance, and warns the team about the public health implications of mcr-1 in co-colonized organisms. Which of the following most accurately characterizes the unique public health significance of mcr-1 compared to chromosomally mediated colistin resistance?

• A) mcr-1 is clinically more significant than chromosomal polymyxin resistance because mcr-1-producing organisms have a 3-fold higher mortality rate in clinical infections compared to organisms with chromosomal PmrAB or PhoPQ mutations; this excess mortality is caused by the phosphoethanolamine lipid A modification encoded by mcr-1, which simultaneously increases endotoxin potency and creates a pro-inflammatory cytokine storm that amplifies sepsis severity beyond what the underlying infection would produce
• B) mcr-1 differs from chromosomal resistance because it confers resistance to both colistin and all polymyxin B analogs in development; chromosomal PmrAB mutations confer colistin resistance only, leaving polymyxin B analogs fully active; the discovery of mcr-1 therefore closed the entire polymyxin class pipeline and explains why the WHO declared a global colistin resistance emergency in 2016 specifically in response to the mcr-1 finding
• C) mcr-1 is clinically equivalent to chromosomal polymyxin resistance in individual patient management but epidemiologically more significant only because of its higher initial prevalence in South Asian ICUs; both mechanisms produce identical colistin MIC increases (typically 4-8 mg/L), and the distinction between them has no bearing on treatment decisions; the relevant difference is geographic and surveillance-based, not pharmacological
• D) mcr-1 is specifically dangerous because it is carried on conjugative plasmids that can transfer the colistin resistance mechanism horizontally to other organisms by conjugation — including to organisms that are already carbapenem-resistant; chromosomal PmrAB and PhoPQ mutations conferring colistin resistance are not horizontally transferable; when mcr-1 transfers to a carbapenem-resistant NDM-producing organism, it creates an organism resistant to carbapenems (NDM) and colistin (mcr-1) simultaneously, potentially with very limited treatment options
• E) mcr-1 is less clinically significant than chromosomal polymyxin resistance because mcr-1 confers only low-level colistin resistance (MIC increase from 0.5 to 2 mg/L) that can be overcome by standard colistin dosing; chromosomal PmrAB mutations produce high-level resistance (MIC >64 mg/L) that cannot be overcome at any colistin dose; the public health concern about mcr-1 is overstated and reflects early alarmism that has not been supported by clinical outcome studies

16. [CASE 4 — QUESTION 4] Continuing with the same patient. She responds to aztreonam-avibactam. During her hospitalization, the fellow asks about cefiderocol — a newer agent that was mentioned in a journal club article as active against pan-resistant organisms including NDM producers. The fellow asks how cefiderocol differs mechanistically from ceftazidime-avibactam and aztreonam-avibactam, and in what clinical scenario cefiderocol would be specifically indicated. Which of the following best characterizes cefiderocol's mechanism and its distinct clinical positioning compared to avibactam-based combinations?

• A) Cefiderocol is mechanistically identical to aztreonam-avibactam but uses a different linker chemistry to conjugate the siderophore to the cephalosporin; its distinct clinical position is that it is approved for soft tissue infections while aztreonam-avibactam is approved only for urinary tract infections; in bloodstream infection the two agents are interchangeable based on formulary availability
• B) Cefiderocol conjugates a catechol siderophore to its cephalosporin scaffold, exploiting TonB-dependent iron uptake systems in Gram-negative bacteria to achieve active transport into the periplasm independent of porin channels; once internalized, it inhibits PBPs in the standard cephalosporin fashion; its clinical advantage is activity against pan-resistant organisms that resist both avibactam-based combinations (including NDM producers) and colistin, making it a distinct last-resort option for organisms with convergent multimechanism resistance
• C) Cefiderocol inhibits both PBPs and NDM-1 through a bifunctional pharmacophore — the cephalosporin ring inhibits PBPs while the catechol moiety chelates the zinc ions in the NDM-1 active site; this dual-target mechanism makes it specifically active against MBL-producing organisms where avibactam-based combinations fail; its clinical position is as a targeted MBL inhibitor plus cell wall synthesis inhibitor in a single molecule
• D) Cefiderocol is a carbapenem analogue with a modified hydroxyethyl group that sterically prevents carbapenemase hydrolysis by all known beta-lactamase classes including MBLs; unlike aztreonam (which avoids hydrolysis by being a poor MBL substrate), cefiderocol actively inhibits KPC, NDM, OXA-48, and MexAB-OprM simultaneously through a single conserved pharmacophore interaction; its clinical position is as a universal carbapenemase inhibitor for all carbapenem-resistant Gram-negative infections
• E) Cefiderocol's activity against pan-resistant organisms reflects its conversion to an active bactericidal free radical metabolite by bacterial nitroreductases; the radical species damages bacterial DNA and membrane proteins through a nitrofurantoin-like mechanism that bypasses all known resistance mechanisms targeting cell wall synthesis; because all Gram-negative bacteria express the target nitroreductase, cefiderocol has no documented resistance mechanism and is considered a last-resort agent with unlimited activity

17. [CASE 5 — QUESTION 1] A 55-year-old man with end-stage renal disease on hemodialysis via a tunneled catheter is admitted with fever, new systolic murmur, and three sets of blood cultures growing Enterococcus faecium. Echocardiography reveals a 1.4 cm tricuspid valve vegetation consistent with infective endocarditis. Susceptibility testing returns: ampicillin resistant (MIC >16 mg/L), vancomycin resistant (MIC >256 mg/L), teicoplanin resistant (MIC >256 mg/L), linezolid susceptible (MIC 1 mg/L), daptomycin susceptible (MIC 2 mg/L). Molecular testing confirms the vanA gene cluster. The cardiac fellow asks why vancomycin fails against this organism despite being the standard agent for serious enterococcal infections in the past, and specifically what biochemical change the vanA cluster produces that eliminates vancomycin activity. Which of the following most accurately explains the vanA mechanism?

• A) The vanA gene cluster encodes a modified version of PBP5 that has 1,000-fold reduced affinity for vancomycin; normally vancomycin binds PBP5 to block peptidoglycan cross-linking, but vanA-modified PBP5 cannot be inhibited by vancomycin at any clinically achievable concentration; beta-lactam antibiotics retain activity against vanA organisms because the PBP5 modification specifically reduces glycopeptide affinity without affecting beta-lactam binding geometry
• B) The vanA gene cluster encodes a vancomycin-inactivating esterase that hydrolyzes the amide bond connecting the heptapeptide core of vancomycin to its sugar residues; the resulting aglycone fragment cannot form the five hydrogen bonds needed for D-Ala-D-Ala binding; this hydrolysis is induced by vancomycin exposure, explaining why susceptibility testing at low vancomycin concentrations does not detect resistance until the enzyme is fully induced at clinical concentrations
• C) The vanA gene cluster reprograms the terminal step of peptidoglycan precursor synthesis: it replaces the normal D-alanine-D-alanine (D-Ala-D-Ala) terminus with D-alanine-D-lactate (D-Ala-D-Lac), a depsipeptide terminus; vancomycin binds D-Ala-D-Ala through five hydrogen bonds including one critical bond to the amide nitrogen of the terminal D-Ala; replacing this amide nitrogen with the ester oxygen of D-Lac eliminates that hydrogen bond and introduces a lone-pair electrostatic repulsion, reducing vancomycin binding affinity approximately 1,000-fold and rendering standard vancomycin concentrations clinically ineffective
• D) The vanA gene cluster encodes a serine beta-lactamase-like enzyme that specifically hydrolyzes the glycopeptide backbone of vancomycin at its C-terminal glycine residue; the resulting deglycinated vancomycin cannot form the D-Ala-D-Ala complex required for transpeptidase inhibition; teicoplanin resistance occurs by the same mechanism because its glycopeptide backbone is cleaved at the same glycine position, while daptomycin is spared because it lacks the susceptible glycine
• E) The vanA gene cluster eliminates all bacterial cell wall synthesis by shutting down the MurA enzyme responsible for the first step of peptidoglycan precursor production; vancomycin and teicoplanin therefore have no target to bind because no D-Ala-D-Ala-containing precursors are produced; the organism survives because VanA-type enterococci have evolved an alternative cell wall synthesis pathway using a non-peptidoglycan polysaccharide structure that is not recognized by any currently available antibiotic

18. [CASE 5 — QUESTION 2] Continuing with the same patient. The infectious disease attending selects daptomycin as the primary therapeutic agent for this VRE E. faecium endocarditis. The fellow asks why the attending is ordering a higher daptomycin dose than the fellow has seen used for VRE bacteremia without endocarditis in other patients, and whether the higher dose carries additional risks. Which of the following best explains the rationale for high-dose daptomycin in VRE endocarditis and the pharmacodynamic justification for dose escalation above the standard bacteremia dose?

• A) The higher daptomycin dose in endocarditis is a pharmacokinetic correction for the known sub-therapeutic daptomycin concentrations in cardiac vegetations; a prospective pharmacokinetic study demonstrated that daptomycin concentrations in tricuspid valve vegetations are 30% lower than concurrent serum concentrations, and the FDA approved the higher endocarditis dose specifically to correct this vegetation penetration deficit
• B) Daptomycin dosing for VRE endocarditis is higher than bacteremia dosing because vegetations contain biofilm-embedded organisms in a stationary growth phase; stationary-phase bacteria have reduced membrane potential that partially impairs daptomycin's calcium-dependent membrane insertion; increasing the dose raises the extracellular concentration gradient and increases passive diffusion of daptomycin into biofilm-embedded cells through a concentration-saturation mechanism
• C) The standard daptomycin dose for bacteremia is 4 mg/kg/day; the elevated dose for endocarditis (6 mg/kg/day) is based exclusively on published pharmacoeconomic modeling showing cost-effectiveness at this dose for valve infections; the pharmacodynamic target (AUC/MIC ratio of 666) is achieved at 4 mg/kg/day for bacteremia but requires 6 mg/kg/day for endocarditis based on the vegetation pharmacokinetic correction factor
• D) The higher daptomycin dose is used for VRE endocarditis because the pulmonary surfactant in the right-sided cardiac chambers inactivates daptomycin; because this patient has tricuspid valve endocarditis (right-sided), daptomycin molecules passing through the right heart are exposed to phospholipid surfactant shed from pulmonary circulation, binding the fatty acid tail and rendering daptomycin inactive; the higher dose compensates for this right-side surfactant inactivation
• E) Daptomycin dosing for serious deep-seated infections including endocarditis is 8-10 mg/kg/day (compared to 4-6 mg/kg/day for bacteremia and skin infections) because the pharmacodynamic target for endocarditis requires a higher AUC/MIC and Cmax/MIC to achieve adequate bacterial killing in high-inoculum cardiac vegetation infections; the primary risk of higher dosing is skeletal muscle toxicity (myopathy, elevated CPK) requiring monitoring, and daptomycin should be avoided or used cautiously in patients with pre-existing myopathy or rhabdomyolysis

19. [CASE 5 — QUESTION 3] Continuing with the same patient. He is started on daptomycin 10 mg/kg/day. Initial blood cultures clear on day 4. On day 12 he develops recurrent fever and two repeat blood culture sets grow VRE E. faecium. The daptomycin MIC on the new isolate is 6 mg/L (non-susceptible; baseline was 1 mg/L). CPK is normal. Whole-genome sequencing of the new isolate shows mutations in liaS and cls (cardiolipin synthase) compared to the original isolate. The fellow asks what these mutations do mechanistically and why they produce daptomycin non-susceptibility. Which of the following most accurately explains the mechanism of on-therapy daptomycin resistance through liaFSR and cls mutations?

• A) The liaFSR system is a three-component regulatory cascade (LiaF-LiaSR) that senses membrane stress from daptomycin binding; liaS mutation produces a gain-of-function sensor kinase that constitutively activates LiaR, the response regulator; activated LiaR upregulates expression of genes that alter the cell membrane phospholipid composition — particularly through cls (cardiolipin synthase) upregulation — reducing the net negative surface charge of the membrane and impairing daptomycin's calcium-dependent insertion; the combination of liaS and cls mutations progressively reduces daptomycin activity through a membrane charge adaptation mechanism
• B) The liaFSR system encodes a daptomycin-specific efflux pump of the MATE family that is normally repressed; liaS mutation constitutively derepresses this efflux pump, actively exporting daptomycin from the cell membrane before it can complete depolarization; cls mutations alter the fatty acid composition of the membrane to increase pump stability; the MIC increase from 1 to 6 mg/L reflects accumulation of pumped daptomycin back into the extracellular medium
• C) The liaFSR system encodes a three-component regulatory system that controls expression of the LtaS enzyme (lipoteichoic acid synthase); liaS mutations cause lipoteichoic acid overproduction that creates a negatively charged polymer layer on the cell surface that competitively sequesters daptomycin calcium complexes before they can insert into the membrane; cls mutations produce altered cardiolipin that anchors excess lipoteichoic acid more stably to the membrane
• D) Cardiolipin synthase (cls) mutations in daptomycin-resistant enterococci specifically reduce cardiolipin content in the cell membrane; cardiolipin is the preferred membrane phospholipid for daptomycin insertion and depolarization; loss of cardiolipin reduces the number of available daptomycin insertion sites, decreasing bactericidal efficiency; the MIC increase reflects a stoichiometric reduction in the number of membrane targets available per organism
• E) The liaFSR mutations produce daptomycin resistance by converting the membrane topology from a lipid bilayer to a hexagonal-II phase arrangement in which the inner leaflet of the membrane faces outward; this membrane topology inversion hides all daptomycin binding sites in the membrane interior; cls mutations stabilize the hexagonal-II phase; because this phase change is irreversible once established, daptomycin resistance through liaFSR is permanent and not amenable to combination therapy

20. [CASE 5 — QUESTION 4] Continuing with the same patient. Daptomycin is discontinued due to on-therapy resistance. The isolate's teicoplanin MIC is re-tested and returns as susceptible (MIC 0.5 mg/L). A cardiology fellow suggests using teicoplanin, which is available from a specialty pharmacy, given the confirmed in vitro susceptibility. The infectious disease fellow is uncertain whether to proceed with teicoplanin or to use linezolid, which is also susceptible (MIC 1 mg/L). The infectious disease attending raises an important issue with the teicoplanin susceptibility result. Which of the following correctly identifies the concern with teicoplanin in this vanA VRE isolate and guides the appropriate salvage choice?

• A) Teicoplanin susceptibility in a vanA VRE isolate is reliable for endocarditis treatment when the MIC is below 1 mg/L; the MIC of 0.5 mg/L in this isolate confirms that the vanA cluster in this strain has a promoter mutation reducing expression to a level that achieves less than 50% D-Ala-D-Lac substitution, leaving sufficient D-Ala-D-Ala substrate for teicoplanin binding at the 0.5 mg/L concentration; linezolid should be avoided because it is bacteriostatic and inadequate for endocarditis
• B) Teicoplanin is appropriate as salvage therapy for this vanA VRE endocarditis because the combination of vancomycin resistance and daptomycin non-susceptibility makes this a pan-resistant isolate where all remaining in vitro susceptibilities including teicoplanin must be used; in pan-resistant organisms, reported susceptibilities are clinically actionable even when the resistance mechanism theoretically predicts in vivo failure
• C) Both teicoplanin and linezolid should be avoided in this clinical scenario; the appropriate salvage agent is oritavancin, a lipoglycopeptide with a binding mechanism that overcomes both D-Ala-D-Ala and D-Ala-D-Lac substitutions through extended hydrophobic tail membrane anchoring; oritavancin is the only currently approved agent with documented bactericidal activity against vanA VRE endocarditis and should be requested from the pharmacy immediately
• D) The teicoplanin susceptibility in this vanA VRE isolate is a testing artifact: the vanA regulatory system (VanSA/VanRA) is induced by both vancomycin and teicoplanin clinically, but standard in vitro susceptibility testing does not induce the vanA pathway to its full clinical expression because the testing inoculum and conditions differ from the in vivo environment; the organism will appear susceptible to teicoplanin in vitro but experience induction of full D-Ala-D-Lac production during teicoplanin therapy, leading to clinical failure; linezolid is the appropriate salvage agent
• E) The teicoplanin susceptibility result is accurate and should be used; the vanA gene cluster confers D-Ala-D-Lac modification only in response to vancomycin exposure, and because this patient's isolate has never been exposed to teicoplanin, the D-Ala-D-Lac pathway remains silent; starting teicoplanin instead of vancomycin will avoid activating the vanA pathway and allow teicoplanin to exert its glycopeptide activity on the unmodified D-Ala-D-Ala precursor

21. [CASE 6 — QUESTION 1] A 67-year-old farmer sustains a severe open tibial fracture in an agricultural accident and is transferred from a rural hospital after 18 days of hospitalization for debridement and external fixation. Blood and wound cultures grow pan-resistant Acinetobacter baumannii. Susceptibility testing shows: all carbapenems resistant (meropenem MIC >8 mg/L), ceftazidime resistant, piperacillin-tazobactam resistant, ceftazidime-avibactam resistant (MIC >32/4 mg/L), colistin susceptible (MIC 0.5 mg/L), sulbactam susceptible (MIC 4 mg/L). Rapid molecular testing confirms OXA-23. The infectious disease team is called. The fellow asks what OXA-23 is and how its carbapenem resistance mechanism differs from KPC and NDM. Which of the following correctly characterizes OXA-23 and explains why ceftazidime-avibactam fails?

• A) OXA-23 is a class B metallo-beta-lactamase that uses zinc ions for catalysis, conferring resistance to all beta-lactams including carbapenems and aztreonam; it differs from KPC (class A) in that it is specifically localized to the outer membrane of A. baumannii rather than the periplasm, making it accessible to zinc chelating agents such as EDTA; ceftazidime-avibactam fails because avibactam cannot chelate zinc and therefore cannot inhibit the outer-membrane-localized OXA-23
• B) OXA-23 is a class D oxacillinase — a serine beta-lactamase with the ability to hydrolyze carbapenems using the same serine-based acyl-enzyme mechanism as class A enzymes but with a distinct active site architecture; unlike KPC (class A, inhibited by avibactam) and NDM (class B MBL, not inhibited by avibactam), OXA-48-type class D carbapenemases have variable avibactam susceptibility — OXA-23 is not significantly inhibited by avibactam, explaining ceftazidime-avibactam resistance; OXA-23 also differs from NDM in that it does not require zinc cofactors and is not inhibited by EDTA
• C) OXA-23 is an extended-spectrum class A serine beta-lactamase (similar to CTX-M) that acquired carbapenem hydrolysis through a deletion in the beta-3 strand of the active site; unlike KPC, OXA-23 is inhibited by both avibactam and vaborbactam; ceftazidime-avibactam resistance in this isolate reflects the presence of a co-produced NDM enzyme (common in A. baumannii) that avibactam cannot inhibit — the molecular testing result should be confirmed for NDM before concluding ceftazidime-avibactam failure is due to OXA-23 alone
• D) OXA-23 is a class C cephalosporinase (AmpC-type) that has undergone evolutionary broadening of its substrate spectrum to include carbapenems through selection by sub-therapeutic carbapenem dosing in agricultural livestock; like all AmpC enzymes, OXA-23 is intrinsically resistant to classical beta-lactamase inhibitors (clavulanic acid, tazobactam) but is fully inhibited by avibactam; ceftazidime-avibactam resistance in this isolate indicates a co-produced enzyme separate from OXA-23
• E) OXA-23 is a class A carbapenemase identical in mechanism to KPC but with a different genomic location — KPC is plasmid-encoded while OXA-23 is always chromosomally encoded and constitutively expressed; because OXA-23 and KPC share identical active site architecture, both are inhibited by avibactam; ceftazidime-avibactam resistance in this isolate therefore indicates that the OXA-23 gene has undergone a point mutation generating avibactam resistance analogous to the D179Y mutation seen in avibactam-resistant KPC variants

22. [CASE 6 — QUESTION 2] Continuing with the same patient. The infectious disease team initiates colistin plus sulbactam combination therapy. The fellow asks why sulbactam is included — the isolate is resistant to ampicillin-sulbactam, so why would sulbactam add any benefit? The attending explains that sulbactam has a property that makes it useful against A. baumannii beyond its role as a beta-lactamase inhibitor. Which of the following most accurately explains sulbactam's mechanism of action against A. baumannii and the rationale for including it in combination with colistin for OXA-23 pan-resistant infections?

• A) Sulbactam is included because it inhibits the PhoPQ two-component regulatory system in A. baumannii that normally activates the lipid A modification pathway conferring polymyxin resistance; by blocking PhoPQ signaling, sulbactam prevents lipid A remodeling and maintains colistin's outer membrane binding affinity throughout therapy; this pharmacological synergy is specific to A. baumannii because Enterobacterales lack the sulbactam-susceptible PhoPQ isoform
• B) Sulbactam is included because it potentiates colistin's membrane-disrupting activity through a detergent-synergy mechanism; sulbactam's beta-lactam ring increases the hydrophobicity of the outer membrane lipid A layer, creating sites of reduced membrane integrity that colistin penetrates more efficiently; this pharmacodynamic synergy produces 2-log greater bactericidal killing than colistin alone against OXA-23 A. baumannii in all published time-kill studies
• C) Sulbactam possesses intrinsic antibacterial activity against Acinetobacter species through direct inhibition of penicillin-binding proteins (PBPs) — specifically PBP1 and PBP3 in A. baumannii — independent of its beta-lactamase inhibitor function; while ampicillin-sulbactam is reported resistant (because OXA-23 hydrolyzes the ampicillin component), sulbactam alone retains PBP inhibitory activity; combining sulbactam with colistin provides a second mechanism targeting cell wall synthesis to complement colistin's membrane-disrupting activity
• D) Sulbactam is included because its diazabicyclooctane core structure inhibits OXA-23 through the same mechanism as avibactam; sulbactam-mediated OXA-23 inhibition protects co-administered antibiotics from carbapenemase hydrolysis; the ampicillin-sulbactam resistance on the susceptibility panel reflects testing of the ampicillin component only, not the sulbactam component — sulbactam's OXA-23 inhibitory activity is confirmed by MIC 4 mg/L (susceptible), and the combination restores the entire beta-lactam class to activity
• E) Sulbactam is included because A. baumannii's outer membrane is uniquely permeable to sulbactam's sulfone group, allowing sulbactam to accumulate in the cytoplasm where it inhibits an A. baumannii-specific peptidoglycan hydrolase (LytA-2) that normally degrades the cross-linked peptidoglycan layer; inhibiting LytA-2 prevents cell wall remodeling required for A. baumannii's characteristic dessication resistance, reducing environmental persistence of the organism rather than directly killing it

23. [CASE 6 — QUESTION 3] Continuing with the same patient. He is started on colistin plus sulbactam. On day 5, wound cultures show A. baumannii with a colistin MIC now reported as 16 mg/L (resistant; baseline MIC was 0.5 mg/L). The sulbactam MIC is unchanged at 4 mg/L. The fellow asks whether this represents a new mutation or a pre-existing resistant subpopulation and how to distinguish these mechanisms clinically. The attending explains the concept of heteroresistance and its implication for combination therapy. Which of the following most accurately distinguishes heteroresistance-driven colistin resistance from true de novo mutational resistance emergence, and what is the clinical implication?

• A) Heteroresistance and de novo mutational resistance are clinically indistinguishable after colistin therapy because both produce the same final phenotype — high MIC resistant colonies — and neither can be reverted by discontinuing colistin; the only way to distinguish them is by whole-genome sequencing of baseline and resistant isolates, which is not clinically actionable because the treatment decision (abandon colistin, add a second mechanism) is identical regardless of which mechanism operated
• B) De novo mutational resistance in A. baumannii during colistin therapy characteristically occurs within 24-48 hours of starting therapy and typically produces MIC increases greater than 64 mg/L in a single step; heteroresistance by contrast produces gradual stepwise MIC increases of 2-fold per day over the full course of therapy; the gradual stepwise increase to MIC 16 mg/L by day 5 is more consistent with true de novo mutational resistance than heteroresistance, requiring immediate colistin discontinuation and switch to an alternative agent
• C) Heteroresistance is only clinically relevant for A. baumannii; Enterobacterales do not exhibit colistin heteroresistance because their PhoPQ regulatory systems cannot generate resistant subpopulations at the frequencies required for clinically significant selective amplification during standard colistin therapy — colistin resistance emergence in Enterobacterales during therapy always reflects horizontal mcr-1 plasmid acquisition rather than heteroresistance
• D) The MIC increase from 0.5 to 16 mg/L by day 5 definitively indicates de novo mutation in the lpxA gene encoding lipid A biosynthesis; this mutation frequency (one per 10^5 bacteria) combined with the high bacterial burden in wound infection produces visible resistance within the standard 5-day window; heteroresistance would have been detected at baseline by population analysis profiling before starting colistin therapy and can be excluded if baseline PAP was not performed
• E) Heteroresistance describes the presence of pre-existing colistin-resistant subpopulations (at frequencies of 10^-6 to 10^-7) within an isolate that tests susceptible at standard MIC inocula; colistin monotherapy selects and amplifies these subpopulations, converting the clinical isolate to apparent resistance within days — a predictable consequence of monotherapy that does not require new mutation; the continued sulbactam susceptibility and unchanged sulbactam MIC support that this is selective amplification of a pre-existing heteroresistant subpopulation rather than generalized mutational resistance acquisition, reinforcing the value of combination therapy

24. [CASE 6 — QUESTION 4] Continuing with the same patient. By day 7 the isolate is now fully colistin-resistant (confirmed heteroresistance amplification) and sulbactam MIC has risen to 16 mg/L (resistant) after further selection. Cefiderocol susceptibility is ordered emergently and returns susceptible (MIC 0.5 mg/L). The fellow asks whether cefiderocol is appropriate and requests an explanation of why cefiderocol retains activity against an organism that has developed resistance to both colistin and sulbactam. Which of the following most accurately explains why cefiderocol retains activity against this pan-resistant A. baumannii and why its entry mechanism is distinct from conventional antibiotics?

• A) Cefiderocol retains activity against pan-resistant A. baumannii because it is transported into the periplasm via TonB-dependent siderophore iron uptake receptors expressed on the bacterial outer membrane; by mimicking an iron-siderophore complex, cefiderocol achieves active periplasmic entry independent of conventional porin channels, bypassing both porin-loss resistance (which reduces conventional antibiotic permeability) and efflux pump overexpression (which removes conventional antibiotics from the periplasm); once inside, it inhibits PBPs in the standard cephalosporin fashion; the OXA-23 carbapenemase does not efficiently hydrolyze cefiderocol's cephalosporin ring, contributing to retained susceptibility despite broad beta-lactamase resistance
• B) Cefiderocol retains activity because it directly inhibits OXA-23 through a boronate pharmacophore that is structurally similar to vaborbactam's cyclic boronate; by inhibiting OXA-23, cefiderocol both prevents its own hydrolysis and restores activity to co-administered carbapenems; the mechanism is similar to meropenem-vaborbactam but uses cefiderocol as the combined antibiotic-inhibitor scaffold rather than a separate inhibitor molecule
• C) Cefiderocol's retained activity reflects its activation by an A. baumannii-specific oxidoreductase that converts the cephalosporin prodrug to a bactericidal reactive oxygen species inside the cell; because colistin and sulbactam resistance mechanisms (lipid A modification and PBP mutations respectively) do not reduce oxidoreductase expression, the bactericidal pathway remains fully active; cefiderocol is essentially a targeted nitrofurantoin derivative that produces A. baumannii-specific radical damage
• D) Cefiderocol bypasses resistance because it targets a newly identified essential outer membrane protein (OmpAB-7) that is constitutively expressed in all A. baumannii strains regardless of carbapenem or polymyxin resistance; by binding OmpAB-7 irreversibly, cefiderocol disrupts the Bam complex responsible for outer membrane protein assembly, causing outer membrane integrity failure; because OmpAB-7 has not been reported as a resistance target in any A. baumannii clinical isolate, cefiderocol is considered resistance-proof against Acinetobacter
• E) Cefiderocol retains activity because A. baumannii's colistin resistance mechanism (lipid A phosphoethanolamine modification by PmrC) paradoxically increases cefiderocol binding affinity; the phosphoethanolamine groups added to lipid A serve as high-affinity binding sites for cefiderocol's catechol siderophore moiety, increasing periplasmic drug delivery 10-fold above what is achieved in colistin-susceptible strains; OXA-23 pan-resistant organisms that acquire colistin resistance therefore become more susceptible to cefiderocol, explaining the clinical observation of retained cefiderocol susceptibility in pan-resistant strains

25. [CASE 7 — QUESTION 1] A 73-year-old man with chronic obstructive pulmonary disease (COPD) and a prior history of Pseudomonas aeruginosa pulmonary colonization is intubated for hypoxic respiratory failure and develops ventilator-associated pneumonia on ICU day 6. Bronchoalveolar lavage cultures grow P. aeruginosa. Susceptibility testing returns: imipenem resistant (MIC 16 mg/L), meropenem susceptible (MIC 1 mg/L), ceftazidime susceptible (MIC 4 mg/L), ciprofloxacin susceptible (MIC 0.5 mg/L), tobramycin susceptible (MIC 1 mg/L). Modified carbapenem inactivation method (mCIM) testing is negative for carbapenemase. The fellow notes that the organism is resistant to imipenem but susceptible to meropenem — the opposite of what she expected, since carbapenems are usually grouped together in susceptibility. The attending asks her to identify the most likely resistance mechanism. Which of the following correctly identifies the mechanism and explains the selective imipenem resistance?

• A) The selective imipenem resistance with preserved meropenem susceptibility indicates that the isolate carries an NDM metallo-beta-lactamase with narrow substrate specificity for imipenem due to an active site amino acid substitution; the negative mCIM test is expected for NDM variants with imipenem-specific activity because standard mCIM testing was calibrated for KPC and does not detect imipenem-specific NDM variants; meropenem should be used with full confidence as the carbapenem of choice
• B) The discordant carbapenem susceptibility reflects testing variability rather than a genuine resistance mechanism; imipenem and meropenem are structurally nearly identical and cannot differ in susceptibility against a non-carbapenemase P. aeruginosa isolate; the imipenem result is a false positive caused by antibiotic disk degradation during shipping; repeat testing with fresh imipenem disks would show co-susceptibility, and either carbapenem can be used
• C) The imipenem resistance reflects selective AmpC de-repression in this P. aeruginosa isolate; AmpC in P. aeruginosa efficiently hydrolyzes imipenem (but not meropenem) due to a structural complementarity between imipenem's hydroxyethyl side chain and the AmpC active site; AmpC de-repression is selectively induced by imipenem because imipenem is a stronger transcriptional inducer of the ampD regulatory pathway than meropenem; meropenem is the appropriate definitive therapy
• D) Loss of OprD, the specific outer membrane porin that serves as the primary entry channel for imipenem in P. aeruginosa, combined with constitutive MexAB-OprM efflux pump expression accounts for the selective imipenem resistance; imipenem's periplasmic access depends heavily on OprD diffusion, and porin loss substantially reduces imipenem but not meropenem entry (meropenem depends less on OprD); meropenem is the appropriate definitive carbapenem, and the negative mCIM confirms this is a permeability-efflux mechanism rather than enzymatic carbapenem hydrolysis
• E) The selective imipenem resistance reflects plasmid acquisition of an imipenem-hydrolyzing OXA carbapenemase with narrow substrate specificity; because OXA carbapenemases with imipenem-only activity produce sub-threshold carbapenem inactivation, the mCIM fails to detect them; meropenem should be used but combination with an aminoglycoside is mandatory because the undetected OXA carbapenemase will hydrolyze meropenem within 72 hours of therapy initiation

26. [CASE 7 — QUESTION 2] Continuing with the same patient. He is treated with meropenem. Molecular resistance characterization confirms loss of OprD through a premature stop codon mutation, and also identifies overexpression of MexAB-OprM through a mexR repressor gene loss-of-function mutation. The fellow asks what the clinical significance of the MexAB-OprM overexpression is in addition to OprD loss, since the susceptibility panel showed susceptibility to ceftazidime, ciprofloxacin, and tobramycin. The attending explains that MexAB-OprM overexpression is clinically important even when individual antibiotic classes appear susceptible at baseline. Which of the following correctly identifies the mechanism of MexAB-OprM-mediated resistance and its clinical significance?

• A) MexAB-OprM overexpression confers resistance only to carbapenems in P. aeruginosa because meropenem and imipenem are the only clinically significant MexAB substrates at standard overexpression levels; the susceptibility of ceftazidime, ciprofloxacin, and tobramycin on the panel confirms that MexAB-OprM overexpression in this isolate has not yet reached the concentration threshold required to produce measurable resistance to non-carbapenem drug classes
• B) MexAB-OprM is a resistance-nodulation-division (RND) tripartite efflux complex that actively exports fluoroquinolones, beta-lactams (including meropenem and ceftazidime), tetracyclines, and chloramphenicol across both the inner and outer membranes directly into the extracellular environment; overexpression through mexR repressor loss-of-function simultaneously reduces susceptibility to multiple structurally unrelated drug classes, and even when individual susceptibility tests remain below breakpoints, the narrow margin means that therapy selection pressure is more likely to drive on-therapy resistance emergence across multiple classes
• C) MexAB-OprM is a major facilitator superfamily (MFS) transporter in P. aeruginosa that uses ATP hydrolysis to drive drug extrusion; mexR mutations produce MexAB-OprM overexpression that is clinically significant only for organisms that are already porin-deficient, because MFS transporters require periplasmic drug accumulation to function — without OprD to deliver drugs to the periplasm, MexAB-OprM becomes the only active resistance mechanism and its upregulation in OprD-deficient strains produces pan-class resistance
• D) MexAB-OprM overexpression in P. aeruginosa is clinically relevant only during aminoglycoside therapy because aminoglycosides are the dominant MexAB-OprM substrates; the resistance-nodulation-division family specifically evolved in P. aeruginosa to export aminoglycosides as a defense against aminoglycoside-producing soil bacteria in the organism's natural habitat; fluoroquinolones and beta-lactams are exported by MexCD-OprJ and MexXY-OprM respectively, and MexAB-OprM overexpression does not affect their susceptibility
• E) MexAB-OprM overexpression is clinically beneficial in tobramycin-treated P. aeruginosa because tobramycin competitively inhibits MexAB-OprM transport of meropenem; by blocking meropenem efflux, tobramycin paradoxically increases intracellular meropenem concentrations, producing pharmacodynamic synergy; this is the pharmacological basis for combining tobramycin with meropenem in P. aeruginosa pneumonia

27. [CASE 7 — QUESTION 3] Continuing with the same patient. The ICU team adds tobramycin to meropenem for combination therapy of the P. aeruginosa VAP (initial tobramycin MIC 1 mg/L, susceptible). On day 7 of tobramycin therapy, a repeat bronchoalveolar lavage culture grows P. aeruginosa with tobramycin MIC now 16 mg/L (resistant). Molecular testing of the resistant isolate shows no aminoglycoside-modifying enzyme gene acquisition; whole-genome sequencing identifies overexpression of MexXY-OprM through upregulation of mexY transcript. No aac, aph, or ant genes are detected. The fellow asks why tobramycin resistance emerged without any aminoglycoside-modifying enzyme acquisition and how a different efflux pump became relevant. Which of the following most accurately explains MexXY-OprM-mediated on-therapy tobramycin resistance?

• A) MexXY-OprM is an RND family efflux system in P. aeruginosa with a unique regulatory mechanism: it is inducible by ribosome-targeting antibiotics including aminoglycosides, macrolides, and tetracyclines through a ribosome-sensing pathway where drug binding to the 30S or 50S subunit generates a regulatory signal that upregulates mexY expression; tobramycin therapy itself induced MexXY-OprM overexpression sufficient to raise the tobramycin MIC from 1 to 16 mg/L — a pharmacological paradox where the antibiotic induces resistance to itself through efflux pump induction
• B) MexXY-OprM induction by tobramycin reflects OprD-mediated transport of tobramycin into the periplasm; because this patient already lacks OprD, aminoglycoside entry is reduced, but the residual aminoglycoside that enters through alternative porins selectively induces MexXY-OprM; the resistance emergence is therefore OprD-dependent and would not occur in OprD-intact P. aeruginosa strains exposed to tobramycin
• C) MexXY-OprM overexpression is caused by tobramycin binding to the 16S rRNA of the 30S subunit, which generates N-acetylglucosamine fragments from disrupted peptidoglycan synthesis; these fragments diffuse to the mexZ regulatory region and act as allosteric activators of mexY transcription; resistance emergence is specific to aminoglycosides that target 16S rRNA position A1408 and does not occur with aminoglycosides targeting other ribosomal positions
• D) The tobramycin resistance emergence reflects adaptive enzyme induction rather than efflux; the MexXY-OprM overexpression detected by whole-genome sequencing represents a housekeeping efflux response that parallels, but does not cause, resistance; the actual resistance mechanism is an aac(6')-Ib variant with a novel 3' insertion that is not detected by standard resistance gene PCR panels; the molecular testing false-negative should prompt repeat testing with expanded aminoglycoside resistance gene panels
• E) MexXY-OprM mediates tobramycin resistance through a unique mechanism where tobramycin is sequestered in the outer membrane lipid A layer by electrostatic interaction before reaching the periplasm; MexXY-OprM does not actively transport tobramycin but rather catalyzes the transfer of tobramycin from lipid A back into the extracellular medium; mexY induction by tobramycin reflects a protective membrane remodeling response rather than true efflux pump activity

28. [CASE 7 — QUESTION 4] Continuing with the same patient. Tobramycin is discontinued due to on-therapy resistance emergence. Ciprofloxacin remains susceptible (MIC 0.5 mg/L, well below the resistance breakpoint). The clinical pharmacist proposes adding IV ciprofloxacin to meropenem at a dose specifically optimized for resistance prevention, not just clinical cure. She explains that the dosing goal for ciprofloxacin in P. aeruginosa VAP goes beyond simply selecting a dose that achieves fT>MIC. The attending asks the pharmacist to explain the PK/PD target that governs both efficacy and resistance prevention for fluoroquinolones, and how this relates to the mutant prevention concentration (MPC) concept. Which of the following most accurately characterizes the PK/PD rationale for ciprofloxacin dosing in this P. aeruginosa infection?

• A) The primary PK/PD target for ciprofloxacin is fT>MIC expressed as a percentage of the dosing interval; achieving fT>MIC above 60% for P. aeruginosa is the recommended resistance prevention target because time-dependent killing at concentrations just above the MIC eliminates organisms before they can acquire secondary QRDR mutations; ciprofloxacin 400 mg IV every 8 hours achieves this fT>MIC target and is the recommended standard dose for VAP
• B) The primary PK/PD target for ciprofloxacin resistance prevention is the peak-to-MIC ratio (Cmax/MIC); a Cmax/MIC ratio above 10 eliminates all organisms in a single concentration-dependent killing event before resistant mutants can replicate; once-daily dosing with ciprofloxacin 800 mg achieves Cmax/MIC above 10 against P. aeruginosa MIC 0.5 mg/L and is pharmacodynamically superior to twice-daily or three-times-daily regimens for resistance prevention
• C) The primary PK/PD parameter governing both efficacy and resistance prevention for ciprofloxacin is the AUC24/MIC ratio; a higher AUC/MIC correlates with more complete bacterial killing and maintains drug concentrations above the mutant prevention concentration (MPC — the threshold above which even single-step resistant mutants cannot grow) for a greater proportion of the dosing interval, narrowing the mutant selection window; dosing ciprofloxacin 400 mg IV every 8 hours in a patient with normal renal function achieves AUC24/MIC targets associated with resistance prevention for susceptible P. aeruginosa
• D) The primary PK/PD target for fluoroquinolone resistance prevention is the minimum bactericidal concentration (MBC)/MIC ratio; selecting ciprofloxacin doses that achieve serum concentrations above the MBC (rather than just the MIC) ensures bactericidal rather than bacteriostatic activity; because the P. aeruginosa MBC/MIC ratio for ciprofloxacin is typically 4-8, dosing must be adjusted to achieve Cmax values 4-8-fold above the MIC to prevent resistance; the current MIC of 0.5 mg/L requires Cmax of 4 mg/L, achievable with 600 mg IV doses
• E) Ciprofloxacin dosing for resistance prevention in P. aeruginosa VAP is governed by the trough concentration (Cmin) to MIC ratio; maintaining Cmin/MIC above 2 throughout the dosing interval ensures continuous suppression of resistant mutant subpopulations by maintaining drug concentrations in the bactericidal range at all times; the AUC/MIC and Cmax/MIC parameters are useful for predicting clinical cure but do not predict resistance prevention, which requires continuous concentration maintenance above the MIC